The b 2 -adrenergic receptors are important for adipocyte lipolysis regulation by catecholamines in humans. The b 2 -adrenoceptor gene is highly polymorphic. The role of these genetic variations for adipocyte lipolysis was investigated. DESIGN AND METHODS: Six single-nucleotide polymorphisms (SNPs) in the promotor region and four SNPs in the coding region (leading to amino-acid substitution) of the b 2 -adrenoceptor gene were determined in 141 overweight or obese, but otherwise healthy women. Lipolysis experiments were performed on isolated subcutaneous adipocytes. RESULTS: Three homozygous haplotypes (6/6, 4/4 and 2/2) were found that differed about 500-fold in noradrenaline sensitivity or b 2 -adrenoceptor sensitivity (6/642/244/4, P ¼ 0.01). The haplotypes also differed by 100% in maximum noradrenalineinduced lipolysis rates (6/642/244/4). However, there was no influence on b 1 -, b 3 -or a 2 A-adrenoceptor sensitivity. Heterozygosity at one or several SNPs in the haplotypes influenced the b 2 -adrenoceptor sensitivity significantly. CONCLUSION: Multiple SNPs in the b 2 -adrenoceptor gene form several haplotypes that markedly influence b 2 -receptor function-and catecholamine-induced lipolysis in fat cells. These haplotypes may be important genetic factors behind impaired lipolysis in obesity.
Introduction
Catecholamines are, together with insulin, the major lipolysis-regulating hormones in humans. Resistance to catecholamine-induced lipolysis is frequently observed in obesity as reviewed, 1 and is at least in part due to the impaired function of adipocyte b 2 -adrenoceptors 2 . This receptor coexists with the two other lipolytic adrenoceptors b 1 and b 3 , and with the antilipolytic a 2 A-adrenoceptor in human fat cells. 1, 3 The b 2 -adrenoceptor gene lacks introns and encodes, besides the receptor, a leader cistron protein; the latter regulates the amount of b 2 -receptor present in the cell. 4 The b 2 -adrenoceptor gene is highly polymorphic. Three singlenucleotide polymorphisms (SNPs) in the exons and one in the leader cistron protein are described, and each one leads to amino-acid substitution. 4 When these SNPs are individually investigated in airway smooth muscle cells and transfected cell lines, each of them induces a marked variation in b 2 -adrenoceptor function. [5] [6] [7] [8] [9] Arg19Cys in the leader cistron protein modulates receptor translation. 8 Arg16Gly and
Gln27Glu alter cellular trafficking and densensitization of the receptor. 6, 7, 9 Thr164Ile alters agonist binding and coupling of the b 2 -receptor to the intracellular signaling system. 5 Some of these receptor variants (ie Arg16Gly and Thr164Ile) also influence lipolysis regulation in subcutaneous fat cells. 10, 11 Furthermore, several SNPs are described in the promotor region of the b 2 -adrenoceptor gene. 12 Recent studies have shown that SNPs in the putative promotor, the leader cistron and the exon are linked and form distinct haplotypes. 13 Some of these haplotypes are common and influence the bronchodilatator response to b-adrenergic agonists in asthmatic subjects and the b 2 -adrenergic receptor function in transfected cell lines. 13 The effects of the haplotypes cannot be predicted from the effect of the individual SNPs when they are studied in recombinant cells. 13 It is unknown so far as to whether b 2 -receptor gene haplotypes influence lipolysis in fat cells. In the present study, we have investigated the importance of b 2 -adrenoceptor gene haplotypes for adrenergic regulation of lipolysis in isolated subcutaneous human fat cells of 141 women with increased body fat content, but who were otherwise healthy. We genotyped for the 10 previously described SNPs in the promotor leader cistron and receptor coding regions. 13 Two common and one less common homozygous haplotypes were identified. All of them markedly influenced adipocyte lipolysis.
Materials and methods

Subjects
The study comprised 141 women born in Scandinavia who were overweight or obese. Overweight was defined as a body mass index (BMI) above 25 kg/m 2 according to WHO. They were otherwise healthy and took no regular medication (including estrogens). None was completely sedentary or involved in athletic performance. They were recruited in a consecutive manner in order to study SNPs in candidate genes for lipolysis regulation. BMI and age ranged from 25 to 61 kg/ m 2 and from 18 to 69 y, respectively. In all, 21 women were postmenopausal as defined as last menstruation since 42 y.
The women came to the laboratory in the morning after an overnight fast. A venous blood sample was obtained for the extraction of DNA as described. 10 A subcutaneous fat biopsy (about 2-3 g) was obtained as described, 2 and immediately processed for lipolysis experiments. In case some tissue was left over, it was frozen in liquid nitrogen and stored at À701C for subsequent protein determination. The study was approved by the committee on ethics at Huddinge University Hospital. It was explained in detail to each participant and her consent was obtained.
Lipolysis experiments
Lipolysis and fat cell volume and number were investigated exactly as described previously. 2 In brief, isolated fat cells were prepared following digestion with collagenase. Fat cell diameter was determined and fat cell volume and number of fat cells incubated were calculated accounting to a formula. 2 Diluted cell suspensions were incubated for 2 h at 371C with air as a gas phase in a medium (pH 7.4) containing albumin, glucose and ascorbic acid. At the end of incubation, an aliquot of the medium was removed for the analysis of glycerol that was used as a lipolysis index and expressed as glycerol release per time unit and per fat cell. The following agents were added in increasing concentrations (10
À12
À10
À3 mol/l dependent on previous knowledge of the lipolysis performance of each of the drugs) to the medium: noradrenaline (a natural catecholamine), dobutamine (a selective b 1 -adrenergic agonist), terbutaline (a selective b 2 -adrenergic agonist), CGP12177 (a selective b 3 -adrenergic agonist), clonidine (a selective a 2 -adrenoceptor agonist), forskolin (a selective stimulator of adenylyl cyclase) and dibutyryl cyclic AMP (a phosphodiesterase-resistant cyclic AMP analogue). The latter two agents were used in order to study if b 2 -receptor gene polymorphism might alter lipolysis regulation at postreceptor levels. Under these dilute incubation conditions, there is no influence of adenosine leaking out of the medium on lipolysis induced by lipolytic agents. However, the antilipolytic effect of clonidine might be influenced. Therefore, in the clonidine experiments adenosine deaminase (1 U/ml) was added to the medium to counteract minor adenosine effects. The concentrationresponse experiments with forskolin and dibutyryl cyclic AMP were analyzed for glycerol release at maximum effective concentration (responsiveness) because these agents are not receptor agonists. For the selective receptor agonists CGP 12177, terbutaline, dobutamine and clonidine, the concentration-response curves were analyzed for half maximum effective concentration (EC 50 ). These values were converted to pD 2 , which is the negative logarithm of EC 50 (mol/l). Changes in pD 2 for lipolysis of receptor-selective agonists reflect alterations in signal transduction at the receptor and near the receptor levels. 14 Noradrenaline was analyzed for pD 2 and responsiveness. In all experiments and with all drugs, we obtained a maximum effect so that it was always possible to calculate pD 2 or responsiveness.
Genotyping
We genotyped all subjects for the four coding SNPs in the b 2 -adrenoceptor gene. 13 Selected subjects were also genotyped for the six reported SNPs in the putative promotor region. 13 Genotyping for the polymorphisms at codon 16 (Arg/Gly), 27 (Gln/Glu) and 164 (Thr/Ile) in the b 2 -receptor protein was carried out exactly as described. 10 These amino-acid changes correspond to the nucleotide changes A/G, C/G and C/T at positions 46, 79 and 491, respectively, in the b 2 -adrenoceptor gene (the first nucleotide in the start codon being þ 1). The Cys/Arg polymorphism at codon 19 in the leader ciston protein (corresponding to nucleotides T/C at position À47) was determined with methods based on polymerase chain reaction (PCR) as follows. A PCR fragment was amplified with forward primer 5 0 -TGAGTGTGCAGGACGAGTCC and reverse primer 5 0 -ATTGGGTGCCAGCAAGAAGG, followed by digestion with restriction enzyme MspAII. The accuracy of genotyping the Cys19Arg polymorphism was confirmed by direct sequencing. Sequencing was used for genotyping of the À1023, À709, À654, À468, À367 variants. A 1241-bp section spanning from position À1093 to þ 148 was amplified by PCR with forward primer 5 0 -CTGTCTTCATGCCTGCAAATTCC and reverse primer 5 0 -CAAACACGATGGCCAGGACGATGAGAG. This PCR fragment was used as a template for further amplifications as part of the Taq DyeDeoxy terminator cycle-sequencing system (Perking-Elmer Corp, Boston, MA, USA) with sequencing primers 5 0 -CCTGCAAATTCCTAAGGA and 5 0 -TGTGCTGCCCTCTGCCTTGA. One noncoding SNP in the leader cistron region at position À20 and two noncoding SNPs in the b 2 -adrenoceptor region at positions 252 and 523 b-2 adrenoceptor gene haplotypes and lipolysis P Eriksson et al have been reported. 13 These SNPs were not genotyped in the present study.
Western blot experiments
The measurements of protein content of b 2 -adrenoceptor in fat cells required at least 300 mg of tissue. As priority was given to lipolysis experiments, we had only sufficient amount of tissue left over for Western blot experiments in a limited number of subjects. The Western blot experiments were performed exactly as described. 15 In brief, adipose proteins were extracted and 100 mg of total protein was separated by SDS-PAGE. b 2 -adrenoceptor protein was probed with a specific antibody (Biotechnology, Santa Cruz, CA, USA). Blots were developed by chemiluminescence and scanned. Finally, the protein was quantified by NIH Software (National Institute of Health, Bethesda, MA, USA).
Statistical methods
Values are mean7standard error (s.e.). They were compared using Student's unpaired t-test, analysis of variance (ANOVA) and analysis of covariance (ANCOVA) including BMI, age or menopause as covariants. Fischer's posthoc test was used in the ANOVA analysis. All tests were two-sided and a P-value of 0.05 or less was considered to be statistically significant.
Results
Genotyping
All subjects were genotyped for SNPs À47, 46, 79 and 491. These SNPs correspond to Cys19Arg in the leader cistron protein and Arg16Gly, Gln27Glu and Thr164Ile in the b 2 -adrenoceptor protein. The frequency of distribution of each of these polymorphisms is shown in Table 1 . The distribution for each SNP was in a Hardy-Weinberg equilibrium (ie the found distribution did not deviate from the expected one). Some of these SNPs were in partial linkage disequilibrium. These were Gly16Gly-Glu27Glu, Arg19Arg-Glu27Glu and Arg19Arg-Gly16Gly. This is in accordance with the earlier observations. 9,10,13 Other combinations had low levels of linkage disequilibrium. We next identified the different haplotypes that are formed by the four polymorphisms (Table 1 ). In total, 19 haplotype combinations were found. Their distribution did not differ from the Hardy-Weinberg equilibrium. Five common (each found in 410% of the population) and one less common homozygous combination were found and considered for further analysis. The remaining haplotypes were uncommon heterozygous or homozygous combinations. Three homozygous haplotypes were analyzed further. These were Arg19Arg-Gly16Gly-Glu27/ Glu-Thr164Thr (termed the A haplotype, n ¼ 32), Cys19Cys-Arg16Arg-Gln27Gln-Thr164Thr (termed the D haplotype, n ¼ 22) and Cys19Cys-Gly16Gly-Gln27Gln-Thr164Thr (termed the F-haplotype, n ¼ 5). All carriers of these three haplotypes were genotyped for the six SNPs in the promotor region. All carriers of the A haplotype were homozygous for nucleotides A,C,G,G,C,C at positions À1023, À709, À654, À468, À406, À367 in the gene. All carriers of the D haplotype were homozygous for nucleotides G,C,A,C,C,T at the positions described above. All carriers of the F haplotype were homozygous for nucleotides G,C,G,C,C,T at the mentioned positions. On the basis of these genotyping data, we constructed three homozygous haplotypes at positions À1023, À709, À654, À468, À406, À367, À47, 46, 79, 491, namely ACGGCCCGGC (n ¼ 32) termed haplotype 2/2, CGACCTTACC (n ¼ 22) termed haplotype 4/4 and G,C,G,C,C,T,T,G,C,C (n ¼ 5) termed 6/6. We used this terminology because the haplotypes were almost identical to those described and named earlier. 13 In the earlier study, genotyping of nucleotides at positions 252 and 523 was also used to construct the haplotypes. 13 However, variations at these two positions determine only haplotypes 6/6, 10/10 and 11/11. 7 It is very unlikely that haplotypes 10/10 and 11/11 are present in our study population because the allele frequency is o1% among Caucasians. 13 Even if the 10 or 11 haplotypes were incorrectly defined as 6/6 haplotype, it would probably not lead to phenotypic effects because SNPs 252 and 523 are noncoding variants. The remaining 82 subjects were referred to as haplotype X/X.
Clinical data
The clinical data for the different haplotypes are shown in Table 2 . There was no apparent effect of b 2 -adrenoceptor gene haplotypes on age, BMI or fat cell volume. 
Position +1 is the first nucleotide in the start codon.
b-2 adrenoceptor gene haplotypes and lipolysis P Eriksson et al
Lipolysis investigations
The influence of haplotypes on lipolysis regulation is summarized in Table 3 . None of the haplotypes influenced pD 2 for CGP 12177, dobutamine or clonidine. However, a marked and significant haplotype effect on pD 2 for noradrenaline and terbutaline was recorded. The order of sensitivity for both agonists was 6/642/24X/X44/4. There was a 1.7-1.9 log unit difference in pD 2 between haplotypes 6/6 and 4/4, meaning that noradrenaline and b 2 -receptor sensitivities were about 500 times higher in the former as compared to the latter haplotype. For illustrative purpose, the mean concentration-response curves for terbutaline and dobutamine in 2/2, 4/4 and 6/6 women are shown in Figure 1 . The dobutamine curves were superimposed, whereas the terbutaline curve of 4/4 women was markedly shifted to the right of the curve for 6/6 women; the curve for 2/2 women had an intermediate position.
An examination of the maximum lipolytic effect of adrenaline and of postreceptor acting drugs was also performed ( Table 3 ). The basal lipolysis rate (no agonist present) and the maximum rates induced by forskolin or dibutyryl cyclic AMP were not influenced by haplotypes. In contrast, noradrenaline-induced lipolysis showed a marked and significant variation. The lipolytic effect was 6/642/24X/X,4/4. Haplotype 6/6 had about two times higher rate of lipolysis following noradrenaline stimulation than haplotype 4/4.
The lipolysis data were subjected to further statistical analysis. Responsiveness data and pD 2 data in Table 3 were corrected for variations in BMI or age by using ANCOVA. This correction did not change the statistical results in an important way. Finally, we made a correction for multiple comparisons in the analysis of pD 2 for terbutaline and noradrenaline and for noradrenaline responsiveness bearing in mind that four different adrenergic agonists were analyzed together in pD2 analysis and three different agents in the responsiveness analysis. We used the formula: P-value in ANOVA times (number of comparisons minus one). According to this formula, P-value corrected for multiple comparison in Table 3 is 0.003 for terbutaline pD 2 , 0.04 for noradrenaline pD 2 and 0.02 for noradrenaline responsiveness. In other words, the results remained statistically significant even after correction for multiple comparisons.
In order to find out the role of heterozygosity in the haplotype effects, we analyzed terbutaline pD 2 for the common heterozygous combinations (ie haplotypes B, C and E in Table 1 ). Values (mean7s.e.) of pD2 for terbutaline with respect to these haplotypes were 7.370.2 (B), 7.570.3 (C) and 7.770.2 (E). The most notable novel observation was the striking differences in the comparison of D (which is the same as 4/4) with E. The former haplotype had lower pD 2 than haplotype E, although the two variants only differed at one amino acid (Arg16Arg vs Arg16Gly at SNP 46). In addition, haplotype A (which is the same as 2/2) had higher terbutaline pD 2 than haplotype B; these haplotypes had different amino-acid combinations at three different SNPs (À47, 46, 79).
Adipocyte content of b 2 -adrenoceptor protein As we only had tissue left for Western blot experiments from a limited number of subjects, the determination of b 2 -adrenoceptor protein could only be carried out in 15 of the Values are mean7s.e. They were compared by ANOVA. n ¼ number of subjects. 
Lipolysis rates
Values are mean7s.e. They were compared by ANOVA. Post hoc analysis showed that pD 2 for terbutaline and noradrenaline differed between all haplotypes (P-values from 0.0001 to 0.05). Post hoc analysis for noradrenaline responsiveness showed a significant difference between 2/2, 4/4 and 6/6 (Pvalues from 0.01 to 0.02), whereas x/x only differed from 2/2 (P ¼ 0.02). pD 2 is the negative logarithm of the molar EC 50 value. Lipolysis is mmol glycerol Â hour À1 Â 10 7 cells. Basal is no lipolytic drug present. n ¼ number of subjects. 
women and 12 of the 4/4women. Each Western blot could handle 18 samples, so two separate blots were required to investigate all subjects. One of the Western blots is depicted in Figure 2 . A specific band at 48 kDa represents the b 2 -adrenoceptor protein. Although b 2 protein levels varied, there was no significant difference between the 2/2 and 4/4 subjects in protein expression (Figure 2 ). These results were confirmed by densitometric scanning for both blots (data not shown).
Influence of menopause Some women were postmenopausal. Although menopause may influence basal adipocyte lipolysis, it has no or little effect on catecholamine-stimulated lipolysis. 16, 17 Nevertheless, we used ANCOVA to test the influence of menopause (n ¼ 20) on the data presented in Table 3 , and found no important effect of this parameter on the reported findings.
Discussion
In this study, we have for the first time investigated the relevance of chromosomal phased SNPs (ie haplotypes) in the b 2 -adrenoceptor gene for lipolysis regulation. Previous experiments with recombinant cells have suggested that multiple SNPs within the human-adrenoceptor gene form haplotypes with biological effects that cannot be predicted from an analysis of individual SNPs as discussed in detail previously. 13 Among healthy overweight/obese women, we identified three homozygous b 2 -adrenoceptor gene haplotypes that we termed 2/2, 4/4 and 6/6 because they are almost identical to previously described haplotypes that have been defined in this manner. 13 As in previously investigated Caucasian populations, the haplotypes 2/2 and 4/4 were common among the Scandinavian women, but haplotype 6/6 was uncommon. Drysdale et al 13 found no subjects homozygous for the six haplotype in their study on Caucasians. This is surprising since the allele was common in their population (13.2%). In other words, our study is the first report on the 6/ 6 haplotype. It is evident that the three haplotypes have markedly different effects on adipocyte lipolysis regulation. Noradrenaline sensitivity was about 500 times higher in women with haplotype 6/6 than in those with haplotype 4/4, whereas women with 2/2 had intermediate sensitivity. This difference could be attributed to a 500-fold increase in b 2 -adrenoceptor sensitivity, which was receptor subtype specific since no haplotype effect was observed on the function of the antilipolytic a 2 A-adrenoceptor or the lipolytic b 3 -or b 1 -adrenoceptors. The genetic variance in the b 2 -adrenoceptor gene has apparent consequences for the natural response of fat cells, that is, lipolysis stimulation by catecholamines. The magnitude of the lipolytic effect of noradrenaline, presently investigated, is dependent on the balance between a 2 Areceptor activity and total b-receptor activity as discussed. 14 The present results show that noradrenaline-induced lipolysis was two times more rapid among 6/6 women than among 4/4 women, whereas 2/2 women had intermediate lipolytic rates. This indicates that the antilipolytic effect of the catecholamine (mediated by a 2 A-adrenergic receptors) becomes more apparent when the b 2 -adrenergic receptor effect is decreased.
Bearing in mind the complexity of adrenoceptor signal transduction, several mechanisms might explain the phenotypic effects of multiple variations in b 2 -adrenoceptor gene structure as discussed. 4 Unfortunately, due to the paucity of tissue, we could not perform detailed molecular investigations on human fat cells. However, some mechanistic insight can be offered. Although responsiveness for noradrenaline differed between the haplotypes, no variation in responsiveness for forskolin (acting at adenylyl cyclase) or dibutyryl cyclic AMP (acting at protein kinase A) was observed. Furthermore, other adrenergic receptors coupled to lipolysis apart from b 2 (ie a 2 A, b 3 and b 1 ) were not influenced and the amount of b 2 -receptor was not altered. These results strongly indicate that the lipolysis effect of the genetic variance is due to specific signals mediated by the b 2 -receptor in fat cells. When haplotype 2/2 and 4/4 were investigated in a murine cell line, mRNA and protein expression was almost twice as high in 2/2 as in 4/4. 13 However, in fat cells, we observed no haplotype effect on the total amount of b 2 -adrenoceptors between 2/2 and 4/4 as assessed with Western blot. This indicates that the haplotypes may induce specific effects in different cell types. It should be noted that we solely investigated subcutaneous fat cells of women who were overweight or obese. In theory, it is possible that other genotype effects are found in lean subjects, in men or in visceral fat cells.
Since haplotyping is time consuming and expensive in comparison with genotyping of a single SNP, it is essential to determine if the examination of 2/2 and 4/4 improves the predictive power. According to Drysdale et al, 13 haplotype 2 is the only haplotype that has a G at position 79 and C at position À47. This means that most 2/2 subjects can be identified by genotyping SNP-47 (Arg19Arg) or SNP 79 (Glu27Glu). However, analysis of all the common haplotypes formed by the exon SNPs (Table 1) revealed that if 2/2 subjects are to be compared with subjects carrying only one haplotype 2 allele, a detailed SNP analysis is necessary because some heterozygous combinations carrying G at SNP 79 and C at SNP-47 differed in phenotype from 2/2, whereas others did not. It is evident that the 4/4 b-2 adrenoceptor gene haplotypes and lipolysis P Eriksson et al or 6/6 haplotypes cannot be identified by genotyping a single SNP. On the other hand, it may be sufficient to only genotype the four coding variants of the SNPs in order to detect 4/4 or 6/6 subjects. However, heterozygous carriers of haplotypes 4 or 6 must be genotyped in detail, including most of the SNPs that are positioned prior to the coding SNPs.
Although it might be possible to determine heterozygous states by algorithms, 13, 18 the number of haplotype combinations would be too large to allow a reliable analysis of the lipolysis data in 141 women. For the same reason, the data with the few 6/6 subjects should be interpreted with some caution because of the risk of type 1 statistical errors. The object of this study was not to examine heterozygous b 2 -adrenoceptor gene haplotypes in detail. However, the data do suggest that some heterozygous 2 and 4 haplotypes have different regulation of adipocytes lipolysis as compared with 2/2 and 4/4 subjects. Most earlier studies of the b 2 -adrenoceptor gene have presented data on one or two SNPs, including our own reports on lipolysis. 10, 11 The present and previous 13 demonstration of the complexity of the b 2 -adrenergic receptor gene polymorphisms strongly suggest that a much more detailed SNP analysis is needed for the understanding of the genetic influence of the b 2 -adrenoceptor on various phenotypes. In summary, this study shows that the b 2 -adrenergic receptor gene forms several haplotypes that markedly influence b 3 -adrenoceptor function and lipolysis regulation by catecholamines in human fat cells.
